UK Markets closed

Guardant Health, Inc. (GH)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
54.18+1.05 (+1.98%)
At close: 04:00PM EDT
54.18 0.00 (0.00%)
After hours: 06:30PM EDT

Guardant Health, Inc.

505 Penobscot Drive
Redwood City, CA 94063
United States
855 698 8887
https://guardanthealth.com

Sector(s)Healthcare
IndustryDiagnostics & Research
Full-time employees1,373

Key executives

NameTitlePayExercisedYear born
Dr. Helmy Eltoukhy Ph.D.Co-Founder, Co-CEO & Chairman13.66k2.32M1979
Dr. AmirAli Talasaz Ph.D.Co-CEO & Director13.27k2.32M1980
Mr. Michael BellChief Financial Officer1.2MN/A1969
Mr. John G. SaiaChief Legal Officer641.22kN/A1973
Dr. Craig Eagle M.D.Chief Medical Officer2.88MN/A1967
Mr. Christopher FreemanChief Commercial Officer of Oncology Bus.740.23kN/A1974
Mr. Andy AmentSr. VP of OperationsN/AN/AN/A
Darya ChudovaSr. VP of TechnologyN/AN/AN/A
Mr. Kumud KaliaChief Information OfficerN/AN/AN/A
Ms. Jennifer HigginsVP of Public AffairsN/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. The company was incorporated in 2011 and is headquartered in Redwood City, California.

Corporate governance

Guardant Health, Inc.’s ISS governance QualityScore as of 31 July 2022 is 9. The pillar scores are Audit: 6; Board: 8; Shareholder rights: 8; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.